Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Librera OncoLink / Repaso de Diarios
Mancuso, AA et al
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 1 de noviembre del 2001
Reviewers: Kenneth Blank, MD
Source: Journal of Clinical Oncology Vol 17, No 2 p 631 1999
At the University of Florida, analysis of local control and larynx preservation by tumor size (comparing tumors >6cm3 vs. <6cm3 ) revealed thatlarger tumors were significantly less likely to be successfully controlled by radiotherapy. This report updates that analysis and examines whetheror not extension into the pre-epiglottic space impacts on local control following definitive radiotherapy.
All patients underwent pre-treatment, contrast-enhanced computed tomography of the neck, and all scans were retrospectively reviewed by twohead and neck radiologists. Tumors were outlined on each image and tumor volumes in cubic centimeters were calculated. Pre-epiglottic spacespread was estimated and expressed as <25%, 25%-75% or >75% of the pre-epiglottic space.
Eighty-nine percent of patients with tumors less than 6cm3 had local control and laryngeal preservation compared to 40% for tumors greater than6cm3 . No patient with a tumor less than 6cm3 developed a complication requiring laryngectomy in contrast to three patients with tumors greaterthan 6cm3. Comparing rates of laryngeal preservation by tumor stage and size revealed that stage T3 tumors larger than 6cm3 had significantlyworse rates of both local control and larynx preservation compared to T1, T2 and T3 tumors less than 6cm3.
The amount of the pre-epiglottic space invasion did not affect local control. However, patients with greater than 25% of the pre-epiglottic spaceinvolved by tumor had lower larynx preservation rates compared to the cohort of patients with less than 25% of the pre-epiglottic space invaded.Specifically, three patients with greater than 25% of the pre-epiglottic space involved had their tumors controlled by radiation but needed alaryngectomy secondary to radiation complications. This result is statistically significant when compared to the number of patients (zero) with lessthan 25% of the pre-epiglottic space involved who had their tumor controlled but necessitated a laryngectomy.
The results of this study are being utilized at the University of Florida to appropriately counsel patients regarding the risk of tumor recurrenceafter definitive radiation, to offer alternative treatments to patients with bulky tumors, and to guide post-radiotherapy follow-up. Specifically,patients with high volume tumors and who are medically fit for surgery are informed that organ preservation surgery may offer superior rates oflarynx preservation than radiotherapy. Another alternative treatment strategy is neoadjuvant chemotherapy. Patients with tumors that wouldrequire a total laryngectomy are offered chemotherapy and those with greater than 50% reduction in tumor size are treated with combinedchemotherapy and hyperfractionated radiotherapy (the total prescribed dose is given over a course of smaller divided doses, called fractions.Hyperfractionation usually involves the delivery of radiation twice a day, as early as possible in the day and then late in the afternoon). Theauthors conclude that the results reported here will lead to more informed decisions, optimizing patient care.
Dr. Giantonio discusses the importance of oncology clinical trials and clarifies some myths about studies. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

